Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Reversible antagonists are dissociable, allowing high agonist concentrations to overcome their effects. Irreversible antagonists form reactive intermediates that permanently bind to alpha-adrenoceptors and cannot be displaced by additional agonists, providing sustained blockade regardless of agonist concentration.

Alpha-1 blockers inhibit alpha-1 adrenoceptors on smooth muscle cells, causing vasodilation. This widening of blood vessels reduces peripheral vascular resistance and lowers blood pressure, making them effective for hypertension management.

Alpha-1 blockers reduce muscle tone in the prostate and bladder neck by inhibiting alpha-1 adrenoceptors on smooth muscle. This relaxation decreases urinary obstruction and alleviates symptoms associated with benign prostatic hyperplasia.

Alpha-2 blockers antagonize presynaptic alpha-2 adrenoceptors, which normally inhibit neurotransmitter release. By blocking these inhibitory receptors, alpha-2 blockers enhance sympathetic neurotransmitter release from presynaptic neurons and activate adrenoceptors of target organs.

Nonselective alpha-blockers interact with both alpha-1 and alpha-2 receptors, causing serious side effects that limit their clinical use for hypertension. However, they are prescribed specifically for pheochromocytoma to prevent dangerous blood pressure elevation from catecholamine release.

Pheochromocytoma is a tumor of catecholamine-secreting chromaffin cells in the adrenal medulla. Excess catecholamine release from this tumor overstimulates adrenergic receptors throughout the body, leading to sustained elevation of blood pressure.

Alpha-1 blockers are used for hypertension and benign prostatic hyperplasia by causing vasodilation and reducing smooth muscle tone. Alpha-2 blockers enhance sympathetic activity and are less commonly used clinically, whereas antagonists pharmacological actions of receptor blockers vary by subtype and clinical indication.